Shilpa Medicare Ltd
Shilpa Medicare Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get Shilpa Medicare Ltd's next results in your feed
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Shilpa Medicare Ltd Q2 FY27 key numbers
- Revenue
- Revenue breakdown 2QFY27: API INR 254 cr (47%), Formulation INR 210 cr (39%), Biologicals INR 65 cr (12%), Others INR 9 cr (2%).
As stated in Shilpa Medicare Ltd's Q2 FY27 investor presentation · published 5 Nov 2026. Reported figures, not investment advice.
Based on Shilpa Medicare Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
2QFY27 total revenue: INR 538 cr, up 45% YoY (from INR 372 cr in 2QFY26). Quarterly EBITDA (2QFY27): INR 151 crore, a 37% YoY increase (from INR 110 crore in 2QFY26).
From Shilpa Medicare Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.
How did Shilpa Medicare's revenue grow in the September 2026 quarter?
- 2QFY27 total revenue: INR 538 cr, up 45% YoY (from INR 372 cr in 2QFY26).
- Revenue breakdown 2QFY27: API INR 254 cr (47%), Formulation INR 210 cr (39%), Biologicals INR 65 cr (12%), Others INR 9 cr (2%).
- 1HFY27 total income: INR 1,007 cr, up 44% YoY (from INR 700 cr in 1HFY26).
- 1HFY27 revenue breakup: API INR 470 cr (47%), Formulation INR 407 cr (40%), Biologicals INR 117 cr (12%), Others 1%.
- API division: highest-ever quarterly revenue at INR 298 cr (incl. captive), ~16% YoY growth in 2QFY27.
- Formulations revenue more than doubled YoY in Europe to INR 82 cr; US revenue INR 35 cr.
- Outlook:
- Several niche launches lined up through FY27 expected to meaningfully contribute to growth.
- Margin improvement anticipated through better utilization of existing assets.
2 more points from Shilpa Medicare Ltd's call on revenue
Create a free account to keep reading this call
What happened to Shilpa Medicare's margins in Q2 FY27?
See what Shilpa Medicare Ltd said on profitability & margins — free account, 30 seconds.
What capex is Shilpa Medicare planning?
- Capital Work in Progress (CWIP) increased to INR 1,051 cr in 1HFY27 from INR 884 cr in FY26, indicating ongoing capex.
- Purchase of Fixed Assets (Net) was INR 252 cr in 1HFY27 vs INR 153 cr in 1HFY26, showing ramp-up in investments.
- Manufacturing capabilities describe advanced facilities including fully automated transdermal patches and oral thin films, biologics drug substance and product manufacturing, as well as complex technologies like ADC, peptides, conjugated proteins.
- Major regulatory accreditations include US FDA, EU GMP, WHO-GMP, TGA, Health Canada, and others, supporting expansion readiness.
2 more points from Shilpa Medicare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Shilpa Medicare raising money or cutting debt?
See what Shilpa Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Shilpa Medicare's order book?
2 more points from Shilpa Medicare Ltd's call on order book
Create a free account to keep reading this call
Shilpa Medicare Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Shilpa Medicare Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 529 |
| Operating profit (EBITDA) | 142 |
| Operating margin | 26.9% |
| Profit before tax | 104 |
| Net profit (PAT) | 79 |
| EPS (₹) | 4.05 |
Source: Shilpa Medicare Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹466 Cr, net profit ₹101 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shilpa Medicare Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Shukra Pharmaceuticals (Q2 FY27)
For the quarter ended September 30, 2026, revenue from operations is ₹4,420.38 Lakhs compared to ₹587.74 Lakhs for the quarter ended September 30, 2025. Key…
- Wanbury (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026 is ₹18,290.97 Lakhs (₹182.91 Crores). Key results statement takeaways from Wanbury Ltd's Q2 FY27
- Influx Healthtech (Q2 FY27)
Revenue from operations for H1 FY27: ₹85.4 crores . Key investor presentation takeaways from Influx Healthtech Ltd's Q2 FY27 investor presentation — and how it
- Unichem Laboratories (Q2 FY27)
Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated). Key results statement takeaways from
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Shilpa Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shilpa Medicare Ltd Q2 FY27 results?
2QFY27 total revenue: INR 538 cr, up 45% YoY (from INR 372 cr in 2QFY26). Quarterly EBITDA (2QFY27): INR 151 crore, a 37% YoY increase (from INR 110 crore in 2QFY26).
What is Shilpa Medicare Ltd share price analysis?
Shilpa Medicare Ltd currently shows a neutral. The stock trades at a P/E of 64.0 with a market cap of ₹18,203 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shilpa Medicare Ltd planning capital expenditure?
Capital Work in Progress (CWIP) increased to INR 1,051 cr in 1HFY27 from INR 884 cr in FY26, indicating ongoing capex.
Keep Shilpa Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.